PL2016080T3 - Pochodne dihydropirazolopirymidynonu - Google Patents

Pochodne dihydropirazolopirymidynonu

Info

Publication number: PL2016080T3
Authority: PL; Poland
Prior art keywords: dihydropyrazolopyrimidinone; derivatives; dihydropyrazolopyrimidinone derivatives
Prior art date: 2006-04-27

Application number

PL07742843T

Other languages

English (en)

Inventor

Toshihiro Sakamoto

Satoshi Sunami

Fuyuki Yamamoto

Kenji Niiyama

Makoto Bamba

Keiji Takahashi

Hidetomo Furuyama

Takeshi Sagara

Sachie Otsuki

Toshihide Nishibata

Takashi Yoshizumi

Hiroshi Hirai

Original Assignee

Msd Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-27

Filing date

2007-04-25

Publication date

2011-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2016080(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-04-25 Application filed by Msd Kk filed Critical Msd Kk

2011-03-31 Publication of PL2016080T3 publication Critical patent/PL2016080T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL07742843T 2006-04-27 2007-04-25 Pochodne dihydropirazolopirymidynonu PL2016080T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2006124208		2006-04-27
PCT/JP2007/059408 WO2007126122A1 (en)	2006-04-27	2007-04-25	Dihydropyrazolopyrimidinone derivatives
EP07742843A EP2016080B1 (en)	2006-04-27	2007-04-25	Dihydropyrazolopyrimidinone derivatives

Publications (1)

Publication Number	Publication Date
PL2016080T3 true PL2016080T3 (pl)	2011-03-31

Family

ID=38655640

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL07742851T PL2017278T3 (pl)	2006-04-27	2007-04-25	Pochodne dihydropirazolopirymidynonu
PL07742843T PL2016080T3 (pl)	2006-04-27	2007-04-25	Pochodne dihydropirazolopirymidynonu

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL07742851T PL2017278T3 (pl)	2006-04-27	2007-04-25	Pochodne dihydropirazolopirymidynonu

Country Status (38)

Country	Link
US (4)	US7834019B2 (pl)
EP (2)	EP2017278B1 (pl)
JP (2)	JP4513919B2 (pl)
KR (1)	KR101409161B1 (pl)
CN (1)	CN101432284B (pl)
AR (1)	AR060635A1 (pl)
AT (1)	ATE475662T1 (pl)
AU (1)	AU2007244185B2 (pl)
BR (1)	BRPI0710081A2 (pl)
CA (1)	CA2650119C (pl)
CR (1)	CR10359A (pl)
CY (2)	CY1111069T1 (pl)
DE (1)	DE602007008085D1 (pl)
DK (2)	DK2017278T3 (pl)
DO (1)	DOP2007000084A (pl)
EC (1)	ECSP088812A (pl)
ES (2)	ES2348751T3 (pl)
GT (1)	GT200800211A (pl)
HN (1)	HN2008001532A (pl)
HR (2)	HRP20161763T1 (pl)
HU (1)	HUE032987T2 (pl)
IL (1)	IL194367A (pl)
LT (1)	LT2017278T (pl)
MA (1)	MA30428B1 (pl)
MX (1)	MX2008013063A (pl)
MY (1)	MY145408A (pl)
NO (1)	NO341617B1 (pl)
NZ (1)	NZ571196A (pl)
PE (1)	PE20080695A1 (pl)
PL (2)	PL2017278T3 (pl)
PT (2)	PT2016080E (pl)
RU (1)	RU2437885C2 (pl)
SI (2)	SI2017278T1 (pl)
SV (1)	SV2009003060A (pl)
TW (1)	TWI409262B (pl)
UA (1)	UA96152C2 (pl)
WO (2)	WO2007126122A1 (pl)
ZA (1)	ZA200807748B (pl)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR060635A1 (es) *	2006-04-27	2008-07-02	Banyu Pharma Co Ltd	Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
JP5411847B2 (ja) *	2007-04-25	2014-02-12	Ｍｓｄ株式会社	Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
WO2008141385A1 (en) *	2007-05-21	2008-11-27	Biota Scientific Management Pty Ltd	Viral polymerase inhibitors
EP2213673B1 (en) *	2007-10-23	2013-06-05	Msd K.K.	Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2303885B1 (en) *	2008-06-12	2013-07-03	Merck Sharp & Dohme Corp.	Process for producing bicycloaniline derivatives
CA2745959A1 (en) *	2008-12-12	2010-06-17	Msd K.K.	Dihydropyrimidopyrimidine derivatives
WO2010076887A1 (en) *	2009-01-05	2010-07-08	Banyu Pharmaceutical Co.,Ltd.	Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
CA2750716A1 (en) *	2009-02-25	2010-09-02	Msd K.K.	Pyrimidopyrimidoindazole derivative
EP2473633A4 (en) *	2009-09-02	2013-03-06	Msd Kk	USE OF ONE OR MORE BIOMARKERS TO IDENTIFY A WEE1 DISEASED PATIENT AND PROCEDURE FOR TREATING CANCER MEDIATED BY DYSFUNCTIONAL OR ABERRANT P53 BY ADMINISTERING A WEE1 HEMMER
US8703779B2 (en)	2009-09-15	2014-04-22	Merck Sharp & Dohme Corp.	Preparation of crystalline forms of dihydropyrazolopyrimidinone
EP2640386B1 (en)	2010-11-16	2017-01-18	Array Biopharma Inc.	Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
EP4223746A1 (en) *	2011-04-27	2023-08-09	Zeon Corporation	Polymerizable compound, polymerizable composition, polymer, and optically anisotropic material
US8796289B2 (en)	2011-07-19	2014-08-05	Abbvie Inc.	Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
WO2013039854A1 (en)	2011-09-15	2013-03-21	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
JP2014530867A (ja)	2011-10-20	2014-11-20	アッヴィ・インコーポレイテッド	キナーゼのピリドピリミジノン阻害剤
CA2864142A1 (en) *	2012-02-23	2013-08-29	Abbvie Inc.	Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (en) *	2012-10-15	2014-04-24	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
DK2925888T3 (en) *	2012-11-28	2017-12-18	Merck Sharp & Dohme	COMPOSITIONS AND METHODS OF CANCER TREATMENT
CA2909160C (en)	2013-04-09	2021-05-25	Lixte Biotechnology, Inc.	Formulations of oxabicycloheptanes and oxabicycloheptenes
GB201306610D0 (en) *	2013-04-11	2013-05-29	Almac Discovery Ltd	Pharmaceutical compounds
GB201322602D0 (en)	2013-12-19	2014-02-05	Almac Discovery Ltd	Pharmaceutical compounds
JP6023902B1 (ja) *	2014-12-17	2016-11-09	Ｄｅｌｔａ−ＦｌｙＰｈａｒｍａ株式会社	高齢又は末期の癌患者を治療又は寛解するための医薬組成物
TW201706258A (zh)	2015-04-17	2017-02-16	艾伯維有限公司	作為ｔｎｆ信號傳遞調節劑之吲唑酮
AR104291A1 (es)	2015-04-17	2017-07-12	Abbvie Inc	Moduladores tricíclicos de la señalización por tnf
TW201702247A (zh)	2015-04-17	2017-01-16	艾伯維有限公司	作為ｔｎｆ信號傳遞調節劑之吲唑酮
DK3345907T3 (da) *	2015-09-01	2020-06-22	Taiho Pharmaceutical Co Ltd	Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
CN105130986B (zh) *	2015-09-30	2017-07-18	广州科擎新药开发有限公司	嘧啶或吡啶并吡啶酮类化合物及其应用
CA3003737C (en) *	2015-11-01	2021-09-14	The Regents Of The University Of Colorado, A Body Corporate	Wee1 kinase inhibitors and methods of making and using the same
GB201612092D0 (en) *	2016-07-12	2016-08-24	Almac Discovery Ltd	Pharmaceutical compounds
WO2018052772A1 (en)	2016-09-15	2018-03-22	Boehringer Ingelheim International Gmbh	Heteroaryl carboxamide compounds as inhibitors of ripk2
CN106719769A (zh) *	2016-11-28	2017-05-31	山东农业大学	一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
JP7246309B2 (ja)	2016-12-08	2023-03-27	リクスト・バイオテクノロジー，インコーポレイテッド	免疫応答を調節するためのオキサビシクロヘプタン
CN110198943B (zh) *	2017-01-23	2021-04-16	石家庄智康弘仁新药开发有限公司	作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
GB201703881D0 (en) *	2017-03-10	2017-04-26	Almac Discovery Ltd	Pharmaceutical compounds
US11248006B2 (en)	2017-03-23	2022-02-15	Shanghai De Novo Pharmatech Co., Ltd.	Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof
SG11201908788YA (en)	2017-03-31	2019-10-30	Seattle Genetics Inc	Combinations of chk1- and wee1 - inhibitors
WO2019028008A1 (en) *	2017-08-01	2019-02-07	Zeno Royalties & Milestones, LLC	1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES
CN109422754A (zh) *	2017-08-24	2019-03-05	上海迪诺医药科技有限公司	吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) *	2017-10-09	2019-04-18	Girafpharma, Llc	HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018347307A1 (en)	2017-10-09	2020-04-23	Nuvation Bio Inc.	Heterocyclic compounds and uses thereof
WO2019085933A1 (zh)	2017-11-01	2019-05-09	南京明德新药研发股份有限公司	作为Wee1抑制剂的大环类化合物及其应用
CN109810111B (zh) *	2017-11-20	2023-10-27	上海医药集团股份有限公司	一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111315747B (zh) *	2018-01-05	2023-05-02	四川科伦博泰生物医药股份有限公司	二氢吡唑酮并嘧啶类化合物及其制备方法和用途
US11479555B2 (en) *	2018-02-23	2022-10-25	Newave Pharmaceutical Inc.	Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
WO2019169065A2 (en) *	2018-02-28	2019-09-06	The Regents Of The University Of Colorado, A Body Corporate	Wee1 kinase inhibitors and methods of treating cancer using the same
EP3762385B1 (en) *	2018-03-09	2025-02-12	Recurium IP Holdings, LLC	Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN108653282B (zh) *	2018-06-28	2020-08-14	中国科学院昆明植物研究所	苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
US12180184B2 (en)	2018-10-26	2024-12-31	Wuxi Biocity Biopharmaceutics Co., Ltd.	Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof
CN113480541B (zh) *	2019-03-07	2022-09-02	湖南化工研究院有限公司	咪唑并吡啶化合物及其中间体的制备方法
KR102697799B1 (ko) *	2019-03-22	2024-08-23	쇼우야오 홀딩스 (베이징) 코., 엘티디.	Wee1 억제제 및 이의 제조 및 용도
CN113939296A (zh)	2019-04-09	2022-01-14	诺维逊生物股份有限公司	杂环化合物及其用途
US20220220115A1 (en) *	2019-04-09	2022-07-14	Nuvation Bio Inc.	Heterocyclic compounds and uses thereof
WO2020210320A1 (en) *	2019-04-11	2020-10-15	Recurium Ip Holdings, Llc	Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
HRP20241008T1 (hr)	2019-04-30	2024-11-08	Wuxi Biocity Biopharmaceutics Co., Ltd.	Kristalni oblik spoja inhibitora wee1 i njegova uporaba
CN112142748B (zh)	2019-06-28	2023-07-04	上海医药集团股份有限公司	一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112142747B (zh) *	2019-06-28	2024-03-01	上海医药集团股份有限公司	一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN114599399A (zh)	2019-10-25	2022-06-07	阿斯利康(瑞典)有限公司	治疗癌症的方法
WO2021127047A1 (en) *	2019-12-20	2021-06-24	Recurium Ip Holdings, Llc	Combinations
CN113387962A (zh) *	2020-03-12	2021-09-14	上海迪诺医药科技有限公司	吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN115698006B (zh) *	2020-06-17	2024-03-29	微境生物医药科技(上海)有限公司	作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物
KR102549484B1 (ko) *	2020-12-08	2023-06-29	한국화학연구원	피라졸로피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 관련 질환의 예방 또는 치료용 약학적 조성물
WO2022171088A1 (zh) *	2021-02-09	2022-08-18	微境生物医药科技(上海)有限公司	吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116848118A (zh) *	2021-02-09	2023-10-03	微境生物医药科技(上海)有限公司	作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) *	2021-02-09	2022-08-18	微境生物医药科技(上海)有限公司	作为Wee-1抑制剂的稠环化合物
CN115197221B (zh) *	2021-04-02	2024-05-24	轩竹(北京)医药科技有限公司	二氢吡唑并嘧啶酮类大环衍生物及其用途
EP4329815A1 (en)	2021-04-29	2024-03-06	Novartis AG	Deubiquitinase-targeting chimeras and related methods
JP2024515318A (ja)	2021-04-30	2024-04-08	ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド	Ｗｅｅ－１阻害剤としての縮合環状化合物、その調製方法およびその使用
CN115403582A (zh)	2021-05-28	2022-11-29	江苏天士力帝益药业有限公司	Wee1抑制剂及其用途
CN115838375A (zh) *	2021-09-18	2023-03-24	优领医药科技(香港)有限公司	含嘧啶并二氢吡唑啉酮类衍生物、其药学上可接受的盐及其制备方法和应用
CN113880844B (zh) *	2021-09-29	2023-02-14	武汉九州钰民医药科技有限公司	Wee1蛋白激酶抑制剂adavosertib的化学合成方法
CN113735863A (zh) *	2021-09-29	2021-12-03	武汉九州钰民医药科技有限公司	Wee1抑制剂adavosertib的制备工艺
CN118176195A (zh) *	2021-11-01	2024-06-11	正大天晴药业集团股份有限公司	吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN116462687B (zh) *	2022-01-18	2025-01-07	江苏天士力帝益药业有限公司	Wee1抑制剂及其制备和用途
CN116836184B (zh) *	2022-03-25	2025-07-25	药雅科技(上海)有限公司	Wee1激酶抑制剂的制备及其应用
CN117402162A (zh)	2022-07-13	2024-01-16	江苏天士力帝益药业有限公司	Wee1抑制剂及其制备和用途
CN115073460B (zh) *	2022-07-13	2023-07-25	苏州施安鼎泰生物医药技术有限公司	一种嘧啶并[5,4-c][2,6]萘啶衍生物及其制备方法以及药物组合物和应用
WO2024012549A1 (zh) *	2022-07-15	2024-01-18	映恩生物制药（苏州）有限公司	一种嘧啶并五元杂环化合物、其制备方法和用途
CN119798282A (zh) *	2023-10-11	2025-04-11	智擎生技制药股份有限公司	基于稠合吡啶环的Myt1抑制剂
TW202519226A (zh)	2023-11-08	2025-05-16	美商艾克塞里克斯公司	使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
OA07174A (fr)	1981-08-24	1984-04-30	May & Baker Ltd	Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja)	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) *	1987-08-26	1997-07-09	三井製薬工業株式会社	ピリミジン類及びその薬学的に許容される塩類
US5223608A (en)	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
HUT70024A (en)	1990-09-28	1995-09-28	Smithkline Beecham Corp	Process for preparing water soluble camptothecin analogs
US5162532A (en)	1990-12-20	1992-11-10	North Carolina State University	Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en)	1990-12-20	1993-04-06	North Carolina State University	Camptothecin intermediates and method of making same
US5247089A (en)	1990-12-20	1993-09-21	North Carolina State University	Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5191082A (en)	1990-12-20	1993-03-02	North Carolina State University	Camptothecin intermediate and method of making camptothecin intermediates
US5243050A (en)	1990-12-20	1993-09-07	North Carolina State University	Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
EP1238986B1 (en)	1992-10-28	2008-06-25	Genentech, Inc.	Use of Vascular endothelial cell growth factor antagonists
JP3025602B2 (ja)	1993-05-21	2000-03-27	デビオファームエス．アー．	光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
AU6267896A (en)	1995-06-07	1996-12-30	Imclone Systems Incorporated	Antibody and antibody fragments for inhibiting the growth oftumors
JP3154399B2 (ja)	1996-07-04	2001-04-09	デビオファームエス．アー．	白金化合物の製造方法
CZ27399A3 (cs) *	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv)	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic quinoline compounds
AU2003224341A1 (en)	2002-04-26	2003-11-10	Warner-Lambert Company Llc	Inhibitors of checkpoint kinases (wee1 and chk1)
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004065378A1 (en)	2003-01-17	2004-08-05	Warner-Lambert Company Llc	2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7407962B2 (en) *	2003-02-07	2008-08-05	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds useful as inhibitors or protein kinases
US7320992B2 (en) *	2003-08-25	2008-01-22	Amgen Inc.	Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en)	2004-05-03	2005-11-10	Pfizer Inc	Inhibitors of checkpoint kinases (Wee1 and Chk1)
CA2569530C (en)	2004-07-01	2013-07-30	Daiichi Asubio Pharma Co.,Ltd.	Thienopyrazole derivative having pde 7 inhibitory activity
AU2006205851A1 (en) *	2005-01-14	2006-07-20	Janssen Pharmaceutica N.V.	5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en)	2005-02-24	2006-08-31	Kemia, Inc.	Modulators of gsk-3 activity
AR060635A1 (es) *	2006-04-27	2008-07-02	Banyu Pharma Co Ltd	Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer

2007
- 2007-04-24 AR ARP070101763A patent/AR060635A1/es active IP Right Grant
- 2007-04-24 PE PE2007000511A patent/PE20080695A1/es active IP Right Grant
- 2007-04-25 PT PT07742843T patent/PT2016080E/pt unknown
- 2007-04-25 DK DK07742851.4T patent/DK2017278T3/en active
- 2007-04-25 ES ES07742843T patent/ES2348751T3/es active Active
- 2007-04-25 PL PL07742851T patent/PL2017278T3/pl unknown
- 2007-04-25 EP EP07742851.4A patent/EP2017278B1/en active Active
- 2007-04-25 EP EP07742843A patent/EP2016080B1/en active Active
- 2007-04-25 RU RU2008146759/04A patent/RU2437885C2/ru active
- 2007-04-25 AU AU2007244185A patent/AU2007244185B2/en not_active Ceased
- 2007-04-25 MX MX2008013063A patent/MX2008013063A/es active IP Right Grant
- 2007-04-25 AT AT07742843T patent/ATE475662T1/de active
- 2007-04-25 SI SI200731875A patent/SI2017278T1/sl unknown
- 2007-04-25 PT PT77428514T patent/PT2017278T/pt unknown
- 2007-04-25 US US11/789,548 patent/US7834019B2/en active Active
- 2007-04-25 PL PL07742843T patent/PL2016080T3/pl unknown
- 2007-04-25 DK DK07742843.1T patent/DK2016080T3/da active
- 2007-04-25 NZ NZ571196A patent/NZ571196A/en not_active IP Right Cessation
- 2007-04-25 LT LTEP07742851.4T patent/LT2017278T/lt unknown
- 2007-04-25 UA UAA200813667A patent/UA96152C2/ru unknown
- 2007-04-25 BR BRPI0710081-7A patent/BRPI0710081A2/pt not_active Application Discontinuation
- 2007-04-25 WO PCT/JP2007/059408 patent/WO2007126122A1/en not_active Ceased
- 2007-04-25 DE DE602007008085T patent/DE602007008085D1/de active Active
- 2007-04-25 HR HRP20161763TT patent/HRP20161763T1/hr unknown
- 2007-04-25 KR KR1020087026239A patent/KR101409161B1/ko active Active
- 2007-04-25 HR HR20100563T patent/HRP20100563T1/hr unknown
- 2007-04-25 CN CN2007800150647A patent/CN101432284B/zh active Active
- 2007-04-25 WO PCT/JP2007/059416 patent/WO2007126128A1/ja not_active Ceased
- 2007-04-25 US US12/226,707 patent/US7935708B2/en active Active
- 2007-04-25 SI SI200730373T patent/SI2016080T1/sl unknown
- 2007-04-25 CA CA2650119A patent/CA2650119C/en active Active
- 2007-04-25 ES ES07742851.4T patent/ES2609087T3/es active Active
- 2007-04-25 HU HUE07742851A patent/HUE032987T2/en unknown
- 2007-04-25 JP JP2008513330A patent/JP4513919B2/ja active Active
- 2007-04-27 TW TW096114902A patent/TWI409262B/zh not_active IP Right Cessation
- 2007-04-27 DO DO2007000084A patent/DOP2007000084A/es unknown
2008
- 2008-09-09 ZA ZA200807748A patent/ZA200807748B/xx unknown
- 2008-09-18 MY MYPI20083651A patent/MY145408A/en unknown
- 2008-09-25 IL IL194367A patent/IL194367A/en active IP Right Grant
- 2008-10-09 EC EC2008008812A patent/ECSP088812A/es unknown
- 2008-10-10 CR CR10359A patent/CR10359A/es unknown
- 2008-10-10 HN HN2008001532A patent/HN2008001532A/es unknown
- 2008-10-10 SV SV2008003060A patent/SV2009003060A/es unknown
- 2008-10-10 GT GT200800211A patent/GT200800211A/es unknown
- 2008-11-24 MA MA31411A patent/MA30428B1/fr unknown
- 2008-11-26 NO NO20084968A patent/NO341617B1/no unknown
2010
- 2010-02-08 JP JP2010025458A patent/JP5167291B2/ja not_active Expired - Fee Related
- 2010-10-27 CY CY20101100973T patent/CY1111069T1/el unknown
2011
- 2011-03-22 US US13/053,798 patent/US8791125B2/en active Active
2014
- 2014-06-24 US US14/312,982 patent/US20140303178A1/en not_active Abandoned
2017
- 2017-01-27 CY CY20171100129T patent/CY1118526T1/el unknown

Also Published As

Publication number	Publication date
PT2017278T (pt)	2017-01-03
US20070254892A1 (en)	2007-11-01
SI2017278T1 (sl)	2017-05-31
WO2007126122A1 (en)	2007-11-08
JP4513919B2 (ja)	2010-07-28
ES2348751T3 (es)	2010-12-13
SV2009003060A (es)	2009-04-28
MY145408A (en)	2012-02-15
CN101432284B (zh)	2012-08-15
US7935708B2 (en)	2011-05-03
CY1111069T1 (el)	2012-05-23
KR20090017491A (ko)	2009-02-18
SI2016080T1 (sl)	2011-03-31
AU2007244185A1 (en)	2007-11-08
HK1132498A1 (en)	2010-02-26
EP2016080A4 (en)	2009-05-13
DK2017278T3 (en)	2017-02-13
HRP20100563T1 (hr)	2010-11-30
HUE032987T2 (en)	2017-11-28
RU2437885C2 (ru)	2011-12-27
DE602007008085D1 (en)	2010-09-09
CR10359A (es)	2009-02-19
CA2650119A1 (en)	2007-11-08
IL194367A0 (en)	2009-08-03
AR060635A1 (es)	2008-07-02
HRP20161763T1 (hr)	2017-02-24
EP2017278A1 (en)	2009-01-21
AU2007244185B2 (en)	2012-10-04
JPWO2007126128A1 (ja)	2009-09-17
JP2010132689A (ja)	2010-06-17
CY1118526T1 (el)	2017-07-12
US8791125B2 (en)	2014-07-29
MA30428B1 (fr)	2009-05-04
RU2008146759A (ru)	2010-06-10
DOP2007000084A (es)	2007-12-31
ECSP088812A (es)	2008-11-27
EP2016080A1 (en)	2009-01-21
EP2016080B1 (en)	2010-07-28
CA2650119C (en)	2017-03-14
PL2017278T3 (pl)	2017-10-31
CN101432284A (zh)	2009-05-13
PT2016080E (pt)	2010-10-14
TWI409262B (zh)	2013-09-21
KR101409161B1 (ko)	2014-06-19
ZA200807748B (en)	2009-10-28
HN2008001532A (es)	2009-06-10
UA96152C2 (en)	2011-10-10
NO20084968L (no)	2008-11-26
US20110189130A1 (en)	2011-08-04
DK2016080T3 (da)	2010-11-22
PE20080695A1 (es)	2008-06-28
WO2007126128A1 (ja)	2007-11-08
MX2008013063A (es)	2008-12-16
ATE475662T1 (de)	2010-08-15
US20140303178A1 (en)	2014-10-09
TW200811176A (en)	2008-03-01
EP2017278B1 (en)	2016-11-02
BRPI0710081A2 (pt)	2011-08-02
JP5167291B2 (ja)	2013-03-21
IL194367A (en)	2014-12-31
ES2609087T3 (es)	2017-04-18
US20100063024A1 (en)	2010-03-11
NZ571196A (en)	2011-03-31
GT200800211A (es)	2009-04-07
NO341617B1 (no)	2017-12-11
LT2017278T (lt)	2017-01-25
EP2017278A4 (en)	2009-04-22
US7834019B2 (en)	2010-11-16

Publication	Publication Date	Title
ZA200807748B (en)	2009-10-28	Dihydropyrazolopyrimidinone derivatives
IL196543A0 (en)	2009-11-18	Pyridizinone derivatives
IL193641A0 (en)	2009-05-04	Spiroindolinone derivatives
IL195013A0 (en)	2009-08-03	Pyridopyrimidinone derivatives
IL198319A0 (en)	2010-02-17	Spiroindolinone derivatives
IL195422A0 (en)	2009-08-03	2-pyrazinecarboxamide derivatives
ZA200805574B (en)	2009-12-30	Indol-3-yl-carbonyl-spiro-piperidine derivatives
EP2009005A4 (en)	2010-06-02	AZOLECARBOXAMIDE DERIVATIVE
IL202020A0 (en)	2010-06-16	Spiroindolinone derivatives
IL196364A0 (en)	2009-09-22	Aminoindazolylurea derivatives
IL198059A0 (en)	2009-12-24	2-aminocarbonyl-pyridine derivatives
ZA200809800B (en)	2010-04-28	2-Thioxanthine derivatives acting as Mpo-inhibitors
IL200618A0 (en)	2010-05-17	Aza-pyridopyrimidinone derivatives
IL193211A0 (en)	2009-02-11	Indazole-heteroaryl derivatives
IL198645A0 (en)	2010-02-17	5-hydroxymethyl-oxazolidin-2-one derivatives
IL197152A0 (en)	2009-11-18	5-phenyl-nicotinamide derivatives
EP2133347A4 (en)	2010-03-17	1-BIARYLAZETIDINONDERIVATE
IL202463A0 (en)	2010-06-30	Sulfonyl-quinoline derivatives
IL202159A0 (en)	2010-06-16	Piperidine-amide derivatives
ZA200807460B (en)	2010-02-24	Spiroindolinone derivatives
IL197239A0 (en)	2009-12-24	Phenyloxyaniline derivatives
GB0614154D0 (en)	2006-08-23	Novel Pyriazine Derivatives
GB0610018D0 (en)	2006-06-28	Benzotriazepinone derivatives
IL198973A0 (en)	2010-02-17	Sulfamatobenzothiophene derivatives
GB0610019D0 (en)	2006-06-28	Benzotriazepinone derivatives